Journal of Clinical Oncology
Articles in this Issue
Immune microenvironment signatures as prognostic biomarkers in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC).
4180 Background: GEP-NEC is an aggressive malignancy with rising incidence and limited therapeutic options. While immune c...
High-dose furmonertinib in <i>EGFR</i> -mutant NSCLC with brain metastases after EGFR-TKI resistance.
e14028 Background: Patients with EGFR-mutant non–small cell lung cancer (NSCLC) who develop central nervous system (CNS) m...
Genomic landscape and precision therapeutics in polycythemia vera: Insights from the AACR Project GENIE.
6595 Background: Polycythemia vera (PV) is a myeloproliferative neoplasm associated with blood thickening and increased ri...
Age-stratified late outcomes following bispecific antibody therapy in multiple myeloma: A real-world 6-month landmark analysis.
7535 Background: Multiple myeloma (MM) predominantly affects older adults, with a median age at diagnosis of 69 years. Und...
Clinical and molecular predictors of postoperative seizure outcomes in adult low-grade glioma.
e14084 Background: Seizures are a common presenting symptom in patients with low-grade glioma (LGG) and significantly impa...
<sup>68</sup> Ga-NODAGA-SNA014 whole-body PET imaging to detect Claudin18.2–positive pancreatic cancer lesions.
3065 Background: 68 Ga-labeled nanobody ( 68 Ga-NODAGA-SNA014)...
Identification of high-grade neuroendocrine carcinoma (HGNEC) biology across tumor types through transcriptomic profiling and validation in lung cancer.
3121 Background: HGNECs, including small-cell (SC) and large-cell (LCNEC), are aggressive malignancies frequently misclass...
Leveraging EMR prompts to promote equitable clinical trial participation in gynecologic oncology: RE-AIM implementation results.
e23294 Background: Lack of diversity and low enrollment limit clinical trial success in gynecologic oncology. Providers re...
Baseline body mass index (BMI) impact in advanced cholangiocarcinoma (CCA) treated with chemo-immunotherapy (Chemo-IO): Overall, sex-based, and site-specific analyses.
e16189 Background: Predictive and prognostic factors in advanced CCA remain limited. Although obesity is a recognized risk...
The cost of inequity: Estimating the impact of delayed access to neoadjuvant pertuzumab in Canada.
e23060 Background: Pertuzumab, when used as a neoadjuvant treatment together with chemotherapy and trastuzumab for early-s...
Real-world outcomes of doxorubicin and paclitaxel in advanced Kaposi sarcoma: A TriNetX retrospective cohort study.
11577 Background: For decades, pegylated liposomal doxorubicin (PLD) and paclitaxel have been standard antineoplastic ther...
Population pharmacokinetic analysis of raludotatug deruxtecan (R-DXd), a cadherin 6 (CDH6)–directed antibody–drug conjugate (ADC), in patients (pts) with advanced ovarian cancer (OC) or renal cell carcinoma (RCC).
5571 Background: R-DXd is a CDH6–directed ADC under clinical investigation for the treatment of pts with advanced or metas...
Donafenib combined with anti–PD-1 antibody as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after resection.
e16266 Background: A growing incidence of hepatocellular carcinoma and its high risk of recurrence after curative-intent t...
Genomic characterization of conventional, dedifferentiated, and mesenchymal chondrosarcoma: A 550-patient multicenter analysis.
11528 Background: The rarity of chondrosarcoma has historically impeded efforts and systematic genomic characterization. H...
Regorafenib in recurrent glioblastoma: Real-world outcomes from a Colombian cohort (REGOMA-COL).
2078 Background: Therapeutic options for recurrent glioblastoma (GBM) remain limited, with historically poor outcomes foll...
Comparative toxicity profile of chimeric antigen receptor T-cell therapy versus bispecific T-cell engagers in multiple myeloma and B-cell lymphomas: A propensity-matched real-world analysis.
e19524 Background: Chimeric antigen receptor T-cell (CAR-T) therapy and bispecific T-cell engagers (BiTEs) are widely used...
Bridging educational and research gaps among young oncologists in Latin America: Results from a multicenter survey.
9032 Background: Strengthening oncology research capacity in LATAM is critical to improving regional cancer outcomes. Earl...
Influence of pharmacologic ALDH2 activation on alcohol-driven tumor progression in ALDH2-deficient esophageal squamous cell carcinoma models.
e15171 Background: Esophageal squamous cell carcinoma (ESCC) is highly prevalent in East Asia and strongly linked to alcoh...
Outcomes of CD-19–directed CAR-T therapy in patients with primary and secondary central nervous system lymphoma: A multi-center observational study.
2038 Background: CD-19 directed chimeric antigen receptor T-Cell (CAR-T) therapies have been approved for the treatment of...
Using digital screening to increase early identification of hereditary breast and ovarian cancer syndrome: A multicenter cluster-randomized trial.
10526 Background: Early identification of hereditary breast and ovarian cancer syndrome (HBOCS) in primary gynecological c...
Real-world characteristics, treatment patterns, and outcomes of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients treated in first-line (1L) in the United States (US) community oncology setting.
e19069 Background: Most US DLBCL patients receive their care in community practices. In that setting, there is greater var...
Socioeconomic and access disparities in ovarian cancer treatment and outcomes: A retrospective cohort study.
e17569 Background: Ovarian cancer ranks eighth in common causes of cancer/cancer-related death worldwide. Its high mortali...
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: Outcomes from the microsatellite instability-high population of the phase 3 KEYNOTE-585 study.
4074 Background: In the randomized phase 3 KEYNOTE-585 study (NCT03221426), perioperative pembrolizumab (pembro) plus chem...
Safety and preliminary efficacy of M9466 (HRS-1167) in combination with abiraterone acetate and prednisone/prednisolone (AA-P) in patients (pts) with metastatic prostate cancer in the phase 1 DDRiver 501 study.
5038 Background: M9466 (HRS-1167) is a highly potent, selective next-generation PARP1 inhibitor being investigated in pts...
Influence of <i>TONSL</i> on tumor suppressor function of <i>RAD51</i> and resistance to CDK4/6 inhibitors in ER+ breast cancer.
1097 Background: Homologous Recombination (HR) and Replication Stress (RS) resolution mechanisms help to maintain genomic...